Source: Docwire News, May 2025
Resistance to targeted therapies continues to pose a significant challenge in treating metastatic melanoma. The tumor microenvironment (TME) plays a crucial role in cancer progression and the development of drug resistance. However, the advancement of such treatments has been hindered by the absence of human in vitro 3D models that accurately replicate the complex interactions between melanoma and the TME.
To overcome this limitation, researchers have developed integrated skin-TME-melanoma organoids (mTMEOs), which incorporate essential components of the melanoma TME. These organoids offer a realistic in vitro platform for studying TME-driven tumor progression and for evaluating potential therapeutic interventions. The results will be presented at the American Society of Clinical